

LISA JOY HANSARD, M.D.
Curriculum Vitae

PLACE OF BIRTH: Lubbock, Texas

OFFICE ADDRESS:

Texas Fertility Center
6500 North Mopac Expressway, Suite 1200
Austin, Texas 78731
(512) 451-0149 / (512) 451-0977 fax
www.txfertility.com

MEDICAL LICENSURES: By Federal Licensing Examination
Texas, granted December 4, 1990

SPECIALTY CERTIFICATION AND DATES:

Board Certified, American Board of Obstetrics and Gynecology	November 1997
Board Certified, Subspecialty Board of Reproductive Endocrinology and Infertility, American Board of Obstetrics and Gynecology	April 1999
Recertification	2007-Present

EDUCATION:

College	Texas A&M University, College Station, Texas B.A, Biology, May 1985
Medical School	Texas A&M College of Medicine, College Station, Texas M.D., June 1989

PROFESSIONAL TRAINING AND ACADEMIC CAREER:

Internship and Residency	Department of Obstetrics and Gynecology, The University of Texas Health Science Center San Antonio, Texas 1989-93
---------------------------------	---

Fellowship	Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, Duke University Medical Center Durham, North Carolina 1993-96
-------------------	---

PROFESSIONAL POSITIONS:

Director, Third Party Reproduction, Texas Fertility Center	2005-Present
Medical Director, Austin Fertility Surgery Center	2015-Present

Governing Board, Bailey Square Surgery Center	2019-Present
Medical Executive Committee, Bailey Square Surgery Center	2013-Present
Clinical Assistant Professor, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical School, Dallas, Texas	2010-2015
Clinical Assistant Professor, Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, Texas	1999-2009
Consultant, Texas Medical Board	2009-Present

HOSPITAL APPOINTMENTS:

North Austin Medical Center, Austin, Texas
 Seton Medical Center, Austin, Texas
 Seton Northwest, Austin, Texas
 St. David's Hospital, Austin, Texas
 South Austin Hospital, Austin, Texas
 Bailey Square Surgical Center, Austin, Texas
 Round Rock Medical Center, Round Rock, Texas

ORGANIZATIONS AND PARTICIPATION:

Fellow, American College of Obstetrics and Gynecology
 Member, American Society of Reproductive Medicine
 Member, Society of Reproductive Endocrinology and Infertility
 Member, Society of Assisted Reproductive Technology
 Member, Texas Assisted Reproductive Technology Society
 Member, Texas Medical Association

PROFESSIONAL AWARDS AND SPECIAL RECOGNITIONS:

J.T. Foundation Scholarship Recipient, 29 th Annual Institute of Alcohol and Drug Abuse,	1986
Berlex Foundation Scholarship Recipient,	1991
Outstanding Research Award, Duke University Medical Center,	1996
Texas Super Doctors	2004-Present
Best Doctors in America	2005-Present
Best Doctors in Texas	2003-Present
Best Doctors in Austin	2004-Present
Patient Choice Award	2008-Present

GRANTS:

Watson Pharmaceuticals “A prospective, randomized controlled trial to assess the effectiveness of luteal phase support using Crinone 8% vaginal gel in clomiphene citrate cycles”

Co-Investigator 2011

EMD Serono, Inc. “A Phase IV multi-national, multicenter, exploratory pharmacogenomics trial to test the importance of identified genetic markers, and potentially identify new markers of extreme ovarian responses to GONAL-f® treatment in women undergoing assisted reproduction technology (ART)”

Co-Investigator 2010

EMD Serono, Inc. “A phase II, multicenter, randomized, assessor blinded, active comparator, dose finding study to evaluate AS900672-enriched versus follitropin alfa (GONAL-f®) in stimulating multiple follicular development in infertile women undergoing assisted reproductive technology (ART)”

Co-Investigator 2008

Duramed, Inc. “A Phase 3 Single-Blind Randomized Study to Compare DR-2011 to Progesterone Vaginal Gel for Luteal Phase Supplementation for In Vitro Fertilization”

Co-Investigator 2008

Serono, Inc. “A Prospective multi center randomized trial comparing a new long-acting recombinant FSH product to Gonal F-RFF in patients undergoing IVF”

Co- Investigator 2007

Serono, Inc. “A Prospective multi center pilot study for the evaluation of an oocyte freezing/thawing method in patients undergoing ICSI”

Co-Investigator 2005

Serono, Inc. “A Prospective, Randomized, Comparative, Single Center Trial to Compare the Safety and Efficacy of Gonal-f RFF versus Gonal-f RFF in combination with Luveris in In-vitro Fertilization”

Co-Investigator 2005

Serono Laboratories, “A Prospective, Randomized, Comparative Multi-Center Trial to Compare the Safety and Efficacy of Gonal F and Lupron Administered as Single and Separate Injections”

Co-Investigator 1999

Ethicon, Inc., “Assessment of the Safety and Efficacy of Cryo-Ablative Reduction of Menstruation”

Co-Investigator 1999

Organon Laboratories, "An Open-Label, Randomized Multicenter Study to Assess the Efficacy and Safety of Follistim Solution Formula Compared to a Freeze-Dried Cake Formulation, for the Induction of Ovulation in Clomiphene Resistant Subjects with Chronic Anovulation"

Co-Investigator

1998

PUBLICATIONS:

Chapters:

Hansard L., Olive D.L.: Ambiguous genitalia. IN: Decision Making in Reproductive Endocrinology and Infertility. W.D. Schlaff and J.A. Rock (eds.), Blackwell Scientific Publications, Boston, Massachusetts, 1993.

Hansard L., Mann L., Olive D.L.: Endometriosis and mullerian anomalies. IN: Congenital Malformations and Their Treatment. B.S. Verkauf and M.A. Bernhisel (eds.), Clinical Practice of Gynecology, (Vol 4.), Elsevier, New York, New York, 1993.

Olive D.L., Hansard L.: Endometriosis. IN: Appleton and Lange Manual of Clinical Gynecology. A.J. Jacobs and M.Gast (eds.), Appleton and Lange, East Norwalk, Connecticut, 1993.

Hansard L.J., Walmer D.K.: Descriptive Histology: the gold standard for clinically evaluating the endometrium. IN: Infertility and Reproductive Medicinc Clinics of North America. B.Y. Karlan and E.S. Surrey (eds.), W.B. Saunders, Philadelphia, Pennsylvania, 1995.

Papers:

Hansard. L.J., Healy-Gardner B.E., Drapkin A.T., Bentley R.C., McLachlan J.A., Walmer D.K.: Human endometrial transforming growth factor- α : a transmembrane, surface epithelial protein that transiently disappears during the midsecretory phase of the menstrual cycle. J Soc Gynecol Invest 1997; 4:160-166.

Szyller A, Silverberg K, Crumb R, Vaughn T, Hansard L, Burger N. Ovarian stromal vascularity evaluated by Doppler correlates with the dose of FSH used during stimulation for IVF-ET. Fertil Steril, 92:S47-8, 2009.

Silverberg K, Vaughn TC, Hansard LJ, Burger NZ, Minter T. Vaginal (Crinone 8%) gel vs intramuscular progesterone in oil for luteal phase support in in vitro fertilization: a large prospective trial. Fertil Steril, 97:344-8, 2012

Abstracts:

Hansard L., Gardner B., Ehrmann M., Bentley R., McLachlan J., Drapkin A., Walmer D.:

Expression of cytoplasmic and extracellular transforming growth factor-alpha antigens in human endometrium during the menstrual cycle correlates with physiologic markers. Accepted for oral presentation at the 51st Annual Meeting of the American Society for Reproductive Medicine, Seattle, Washington, October 12, 1995.

Silverberg K.M., Ormand R.A., Hansard L.J., Turner T., Slapak J., Williamson B., Vaughn T.C.: Ultra-Low Dose Lupron Flare Offers Improved Outcome for Poor Responders. Accepted for oral presentation at the 55th Annual Meeting of the American Society for Reproductive Medicine, Toronto, Canada, September 27, 1999.

Silverberg K.M., Ormand R.A., Hansard L.J., Vaughn T.C.: Clomiphene Citrate Improves Sperm Quality and Fertility in Hypogonadal, Oligospermic Males. Accepted for Presentation at the 55th Annual Meeting of the American Society for Reproductive Medicine, Toronto, Canada, September 29, 1999.

Silverberg K., Montgomery Rice V., Ormand R., Karst A., Vaughn T., Hansard L.: Recombinant Human Follicle Stimulating Hormone (rhFSH, Gonal-F®) and Leuprolide Acetate (LA, Lupron®) Administered in Single or Separate Injections in Women Undergoing In Vitro Fertilization (IVF): Preliminary Results. Accepted for oral presentation at the Annual Meeting of the European Society for Reproduction and Endocrinology. Bologna, Italy, June 25, 2000.

Silverberg, K.M., Ormand R.A., Hansard L.J., Vaughn T.C.: The Intercycle Variability in Patients Treated with Repeated Cycles of Gonadotropins is Due to Intrinsic Factors and is not Eliminated by Recombinant Gonadotropins. Accepted for presentation at The 56th Annual Meeting of the American Society for Reproductive Medicine, San Diego, California, October 25, 2000.

Silverberg, K.M., Ormand R.A., Hansard L.J., Vaughn T.C.: Weight Correlates with Gonadotropin Requirements and Patient Response. Accepted for presentation at the 56th Annual meeting of the American Society for Reproductive Medicine, San Diego, California, October 24, 2000.

Silverberg, K.M., Ormand R., Hansard L.J., Vaughn, T.C.: Poor Response to Ovarian Hyperstimulation Predicts Spontaneous Ovulation. Presented at the 57th Annual Meeting of the American Society for Reproductive Medicine, Orlando, Florida, October 2001.

Silverberg, K.M., Ormand R., Hansard L.J., Vaughn T.C.: Recombinant FSH Provides More Efficient, Cost-Effective Stimulation for Ovulation Induction/Intrauterine Insemination (OI/IUI) Cycles Than Highly Purified Urinary FSH. Presented at the 57th Annual Meeting of the American Society for Reproductive Medicine, Orlando, Florida, October 2001.

Silverberg K.M., Minter T., Hansard L.J., Vaughn T.C.: High order multiples and gonadotropin/IUI cycles: how can we reduce the risks? Presented at the 60th Annual Meeting of the American Society for Reproductive Medicine, Philadelphia, Pennsylvania, October 20, 2004.

Silverberg K.M., Werland H., Turner T., Fields R., Schuster C., Hansard L.J., Vaughn T.C.:

Suboptimal embryo morphology on day 3 does not predict poor pregnancy potential. Presented at the 61st Annual Meeting of the American Society for Reproductive Medicine, Montreal, Canada, October 18, 2005.

Silverberg K.M., Werland H., Turner T., Fields R., Schuster C., Hansard L.J., Vaughn T.C.: Choosing the optimal incubator environment: triple gas vs. 5% CO₂ in air, a prospective, randomized trial. Presented at the 61st Annual Meeting of the American Society for Reproductive Medicine, Montreal, Canada, October 1, 2005.

Silverberg K.M., Werland H., Turner T., Fields R., Crowl C., Hansard L.J., Vaughn T.C.: Determining the Predictive Value of Day 3 Embryonic Morphology and Cell Stage on Ultimate Embryo Quality. Presented at the 62nd Annual Meeting of the American Society for Reproductive Medicine, New Orleans, LA, October 22, 2006

Szyller A, Silverberg K, Crumb R, Vaughn T, Burger N, Hansard L. Ovarian Stromal Vascularity Evaluated By Doppler Correlates With The Dose Of FSH Used During in vitro fertilization(IVF) Stimulation. Presented at the 65th Annual Meeting of the American Society for Reproductive Medicine, Atlanta, GA. October, 2009.

Szyller A, Silverberg K, Crumb R, Vaughn C, Hansard L, Burger N. A Prospective, Observational, Comparative Single Center Trial to Predict In Vitro Fertilization and Embryo Transfer Outcome by Ovarian Ultrasound Doppler Measurements. Annual Meeting of the American Institute of Ultrasound In Medicine, San Diego, CA, March, 2010.

Silverberg K, Vaughn T, Hansard L, Burger N, Minter T. Progesterone Vaginal Gel vs. Intramuscular Progesterone in Oil for Luteal Support in IVF: A Large, Prospective Trial. Presented at the 66th Annual Meeting of the American Society for Reproductive Medicine, Denver, CO. October, 2010

Vaughn T, Silverberg K, Hansard L, Burger N. Selection of Young Patients Using Strict Criteria Allows an Excellent Chance of Pregnancy When Transferring a Single Embryo While Avoiding a High Risk of Multiple Gestation. Presented at the 66th Annual Meeting of the American Society for Reproductive Medicine, Denver, CO. October, 2010

Silverberg KM, Minter TL, Silverberg KM, Vaughn TC, Hansard LJ, Burger NZ. Both AMH and day 3 FSH levels predict IVF stimulatn outcome regardless of patient age; Day 3 estradiol levels are not predictive. Presented at the 68th Annual Meeting of the American Society for Reproductive Medicine, San Diego, CA. October, 2012.

Propst A, Hansard L, Silverberg K, Hegtvedt M, Burger N, Vaughn T. Endometrial receptivity and pregnancy rates are higher after 7 days of progesterone in medicated FET cycles. Presented at the 73rd Annual Meeting of the American Society for Reproductive Medicine, San Antonio, TX, October, 2017.

James, R., A. Picou, L. Hansard, H. Werland, M.D. VerMilyea. (2018) Transfer of completely hatched euploid blastocysts results in significantly lower pregnancy outcomes compared to euploid expanded or hatching blastocysts. ASRM 2018 Scientific Conference, Denver, Colorado